Company Overview - Victory Square Technologies Inc. is a venture builder providing investors access to a diverse portfolio of next-generation technology companies [2][23] - The company operates a business model focused on buying, building, and investing in early-stage tech companies, with a commitment to support them for up to 48 months before they can stand on their own [24][26] Financial Performance - For the first half of 2025, adjusted revenue reached $13.87 million, a 27% increase from $10.97 million in the first half of 2024 [7] - Q2 2025 revenue was $5.38 million, compared to $4.43 million in Q2 2024, marking a 21% year-over-year growth [7] - Adjusted EBITDA for the first half of 2025 was $463 thousand, a significant improvement from a loss of $1.59 million in the first half of 2024 [7] Portfolio Highlights - Victory Square maintains over 25 portfolio companies across sectors including digital health, AI, gaming, climate tech, and pet wellness [5][6] - Hydreight Technologies, a key portfolio company, reported a six-month adjusted revenue of $13.9 million, reflecting a 33% year-over-year growth and achieved its third consecutive profitable quarter [6][8] - Insu Therapeutics is developing a patent-pending oral insulin tablet, with early preclinical trials showing promising results [10][11] Strategic Initiatives - The company is exploring share buybacks to reduce net asset value (NAV) discount and enhance shareholder value [6][16] - Pawsible Ventures, another portfolio company, is focused on pet wellness and telehealth solutions, with plans to launch a fund and incubator program in fall 2025 [12][15] Industry Context - The global diabetes therapeutics market is projected to grow to $118 billion by 2032, with over 500 million people currently living with diabetes [13] - The global pet care market is expected to reach $368 billion by 2030, indicating significant growth potential in the pet wellness sector [14] Future Outlook - The company aims to continue supporting Hydreight's growth, advance Insu Therapeutics towards regulatory milestones, and launch Pawsible Ventures' fund and incubator program [20][21] - Upcoming investor conferences will feature Victory Square and its portfolio companies, providing opportunities for engagement with investors [21]

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Aug. 29, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) investors of a class action representing investors that bought securities between October 9, 2024 and July 10, 2025, inclusive (the "Class Period"). Capricor investors have until September 15, 2025 to file a lead plaintiff motion. Investors are encouraged to contact attorn ...

How A 60-Year-Old Drug Developer Built A $4.4 Billion Biotech Treating ‘Butterfly Skin Disease’ https://t.co/8Jsyec9ypp https://t.co/kVNUuFPy8a ...

SOUTH SAN FRANCISCO, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced that ALX Oncology leadership will participate in both the Cantor Global Healthcare Conference 2025 and H.C. Wainwright 27th Annual Global Investment Conference in New York. The details of the meetings are as follows: Cantor ...

My thesis for Sagimet Biosciences Inc. (NASDAQ: SGMT ) is pretty straightforward: this is a small-cap biotech with a very novel mechanism. Blocking fatty acid synthase could give it a real edge in the MASH market. Denifanstat hasI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foundation gave me an app ...

Core Viewpoint - Vaxart, Inc. has received approval from the Nasdaq Hearings Panel to implement a plan to regain compliance with Nasdaq's minimum bid price requirement, contingent upon completing a reverse stock split and demonstrating compliance by specified deadlines [1][2][5]. Group 1: Compliance Plan - The company must obtain stockholder approval for a reverse stock split by September 5, 2025, complete the reverse stock split by October 6, 2025, and demonstrate compliance with Nasdaq Listing Rule 5550(a)(2) by October 17, 2025 [2][3]. - Vaxart's management presented a compliance plan during a hearing on August 14, 2025, which included changes to the reverse stock split proposal, such as narrowing the proposed ratio and reducing the number of authorized shares [3]. Group 2: Stakeholder Engagement - The company is actively engaging with stockholders to address their questions and concerns, including a virtual fireside chat held on August 20, 2025 [4]. - CEO Steven Lo emphasized the importance of stockholder support for the reverse stock split to secure the company's future on Nasdaq [5]. Group 3: Company Overview - Vaxart is a clinical-stage biotechnology company focused on developing oral recombinant vaccines using a proprietary delivery platform, which allows for storage and shipping without refrigeration [7]. - The company's vaccine development programs include candidates for coronavirus, norovirus, influenza, and a therapeutic vaccine for human papillomavirus (HPV) [7].

How A 60-Year-Old Drug Developer Built A $4.4 Billion Biotech Treating ‘Butterfly Skin Disease’ https://t.co/wYksJ3VJJc https://t.co/eS5N8rS3gB ...

Group 1 - A class action has been filed on behalf of investors who purchased Replimune Group, Inc. (NASDAQ: REPL) securities between November 22, 2024, and July 21, 2025 [1] - Robbins LLP is investigating allegations that Replimune Group, Inc. misled investors regarding the viability of its IGNYTE trial, claiming that the company overstated the trial's prospects and failed to disclose material issues [2] - On July 22, 2025, Replimune announced it received a complete response letter (CRL) from the FDA, indicating that the IGNYTE trial was not considered adequate, leading to a significant stock price drop of $9.52 per share, or 77.24%, closing at $2.80 per share [3] Group 2 - Shareholders interested in participating as lead plaintiffs must file their papers with the court by September 22, 2025, and can remain absent class members if they choose not to participate [4] - Robbins LLP operates on a contingency fee basis, meaning shareholders pay no fees or expenses [5] - The firm has been dedicated to helping shareholders recover losses and improve corporate governance since 2002 [5]

Group 1 - Numerous companies in the healthcare sector are actively developing obesity drugs, which have gained significant attention in the medical field [1] - Viking Therapeutics experienced a nearly 4% increase in share price due to positive research findings related to obesity treatments, outperforming the S&P 500 index's 0.3% rise [1] - The effectiveness of obesity drugs extends beyond weight reduction, showing potential benefits for various health conditions, attracting investor interest [2] Group 2 - A recent study highlighted that GLP-1 agonists, which promote a feeling of satiety, may positively impact hidradenitis suppurativa, a troublesome skin condition [4] - Research published in JAMA Dermatology indicates that GLP-1 agonists possess anti-inflammatory properties and can be beneficial for treating hidradenitis suppurativa [5] - Viking's VK2735, a dual agonist targeting both GLP-1 and GIP receptors, could potentially provide additional value if it proves effective for hidradenitis suppurativa [6]

Core Viewpoint - YD Bio Limited has successfully completed its business combination with Breeze Holdings Acquisition Corp, marking its entry into the public markets and positioning itself as a leader in the biotechnology sector focused on cancer detection and ophthalmologic innovations [1][3][7] Business Combination and PIPE Offering - The business combination was approved by Breeze shareholders on August 14, 2025, and YD Bio's shares will begin trading on Nasdaq under the ticker symbols "YDES" and "YDESW" starting August 29, 2025 [1][7] - The PIPE offering closed concurrently with the business combination, yielding over $11,500,000 to support YD Bio's future operations [2] Company Evolution and Leadership - YD Bio has evolved from a supplier of clinical trial drugs to an innovator in diagnostics and therapeutics, with a focus on delivering solutions that improve global health [6] - The company is led by Dr. Ethan Shen, who has over 30 years of experience in the biomedical field [4][6] Business Model and Strategic Focus - YD Bio's business model emphasizes partnerships with biopharmaceutical companies to develop commercially viable drugs and diagnostics [4] - The company holds multi-decade exclusive licensing agreements and proprietary patented technologies, providing a first-mover advantage in clinical markets [5] Core Programs and Innovations - YD Bio is developing DNA methylation-based cancer detection technology, including tests for early pancreatic cancer detection and recurrent breast cancer monitoring [8] - The company is advancing stem cell and exosome therapies for ocular diseases in collaboration with 3D Global Biotech, with clinical trials planned for 2027 [8] - YD Bio also provides clinical trial and ancillary services, supporting global pharmaceutical companies [8] Market Positioning - The completion of the business combination and PIPE offering positions YD Bio for accelerated innovation and market expansion in the fast-growing healthcare sector [3][6]